Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
8 March 2018
E-001467-18
Question for written answer
to the Commission
Rule 130
Nikos Androulakis (S&D)

 Subject:  Measures to introduce transparency in the pricing of medicines
 Answer(s) 

The absence of a common system for costing medicines in the European Union has caused considerable differences in the pricing of medicines, affecting mainly smaller countries with less bargaining power.

The price of medicines can fluctuate often without obvious reasons, overburdening national budgets and national health systems as well as European consumers. The situation in my country, Greece, is a case in point.

At the same time, Directive 89/105/EEC on transparency, which is thirty years old this year, needs an immediate overhaul, as there have been significant changes regarding medicines in Europe, the most important of which is the advent of generic medicines.

Given that the current system is causing distortions in the European medicines market, while encouraging corruption, can the Commission say:
Will it submit a new proposal for the revision of Directive 89/105 /EEC, following the withdrawal of the previous proposal in 2015?
What action does it intend to take to develop common cost accounting and pricing methods for medicines in the European market?
Original language of question: EL 
Last updated: 23 March 2018Legal notice